Pluristem Therapeutics, Inc. (NASDAQ:PSTI)

CAPS Rating: 1 out of 5

Recs

1
Player Avatar zzlangerhans (99.73) Submitted: 1/15/2013 3:27:33 PM : Underperform Start Price: $3.52 PSTI Score: +13.05

Wow, Pluristem received approval in Germany! Approval to run a phase II trial there, that is. Pluristem CEO seems to be aware that issuing any PR with the word "approval" somewhere in it is good for a momentary 10% spike in share price. Someone should do a study to determine the correlation between these types of announcements and the lockup expiration dates for their dilutive financings.

Featured Broker Partners


Advertisement